| 초록 |
In Atopic dermatitis (AD), overactivity of phosphodiesterase 4 (PDE4) in immune cell leads to inflammation and disease exacerbation. Crisaborole, a nonsteroidal and topical anti-inflammatory PDE4 inhibitor, is currently being investigated for the treatment of mild to moderate AD. In this study, we propose an enhanced crisaborole delivery system which is established by using nanovesicles with immune cell targeting peptide conjugates. To evaluate selectively targeting ability of peptide conjugated nanovesicles, comparison of cellular uptake between immune cells and normal cells is quantified via fluorescence spectrometer. Finally, in vitro specific cell target treatment efficacy demonstrates the practical applicability as drug delivery nanovesicle system in dermal therapy. |
